Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 369-374 , September 2009

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

  • Steven Ferris

      Affiliations

    • Alzheimer's Disease Center, New York University School of Medicine, New York, NY, and Nathan Kline Institute, Orangeburg, NY, USA
    • Corresponding Author InformationCorresponding author. Tel.: 212-263-5703; Fax: 212-263-6991.
    • ,
  • Ralf Ihl

      Affiliations

    • Department of Psychiatry, University of Düsseldorf and Department of Geriatric Psychiatry, Alexian Hospital, Krefeld, Germany
    • ,
  • Philippe Robert

      Affiliations

    • Memory Center, CHU - University of Nice Sophia Antipolis, Nice, France
    • ,
  • Bengt Winblad

      Affiliations

    • Alzheimer Center, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Gudrun Gatz

      Affiliations

    • Merz Pharmaceuticals, Frankfurt am Main, Germany
    • ,
  • Frank Tennigkeit

      Affiliations

    • Merz Pharmaceuticals, Frankfurt am Main, Germany
    • ,
  • Serge Gauthier

      Affiliations

    • McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada

References 

  1. Blair M, Marczinski CA, Davis-Faroque N, Kertesz A. A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc. 2007;13:237–245
  2. Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia. 2004;42:1212–1222
  3. Cosentino S, Scarmeas N, Albert SM, Stern Y. Verbal fluency predicts mortality in Alzheimer disease. Cogn Behav Neurol. 2006;19:123–129
  4. Powell JA, Hale MA, Bayer AJ. Symptoms of communication breakdown in dementia: carers' perceptions. Eur J Disord Commun. 1995;30:65–75
  5. Potkins D, Myint P, Bannister C, Tadros G, Chithramohan R, Swann A, et al. Language impairment in dementia: impact on symptoms and care needs in residential homes. Int J Geriatr Psychiatry. 2003;18:1002–1006
  6. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol [B] Psychol Sci Soc Sci. 2005;60(Suppl):S48–S55
  7. Hendryx-Bedalov PM. Alzheimer's dementia. Coping with communication decline. J Gerontol Nurs. 2000;15:37–47
  8. Saxton J, Swihart AA, McGonigle-Gibson KL, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess. 1990;2:298–303
  9. Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry. 2005;13:999–1005
  10. Panisset M, Roudier M, Saxton J, Boller F. Severe Impairment Battery. A neuropsychological test for severely demented patient. Arch Neurol. 1994;51:41–45
  11. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11:51–56
  12. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's patients. 2009;5:375–9.
  13. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like Memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1:101–110
  14. Seow D, Gauthier S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry. 2007;52:620–629
  15. Homma A, Kitamura S, Yoshimura I. Efficacy of Memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). Eur J Neurol 14.
  16. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of Memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;14:136–143
  17. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA. 2004;291:317–324
  18. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–1341
  19. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  20. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24:653–659
  21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  22. Galasko D, Bennet D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(Suppl):S33–S39
  23. Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Möbius HJ, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm. 2002;62:135–148
  24. Barrett B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making. 2005;25:250–261
  25. Burback D, Molnar FJ, St John P, Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord. 1999;10:534–540
  26. de Vet HC, Terwee CB, Ostelo RW, Beckermann H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes. 2006;4:54
  27. Livingston G, Katona C. The place of Memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry. 2004;19:919–925

PII: S1552-5260(09)01955-4

doi: 10.1016/j.jalz.2009.05.604

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 5 , Pages 369-374 , September 2009

Article Tools

* Image Usage & Resolution